Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    4,766

Stocks News & Analysis

stocks

Fair value upgrade for this ASX income player

Headwinds in listed energy stocks likely to have passed
stocks

The SpaceX IPO and the Elon Musk factor

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks

The ASX’s most shorted stocks in 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,657.502.200.03%
CAC 407,772.4570.500.92%
DAX 4022,562.88262.131.18%
Dow JONES (US)45,216.1449.500.11%
FTSE 10010,127.96160.611.61%
HKSE24,750.79201.09-0.81%
NASDAQ20,794.64153.72-0.73%
Nikkei 22551,885.851,487.22-2.79%
NZX 50 Index12,757.288.360.07%
S&P 5006,343.7225.13-0.39%
S&P/ASX 2008,461.000.100.00%
SSE Composite Index3,923.299.560.24%

Market Movers